Stiripentol and Lumasiran as a Rescue Therapy for Oxalate Nephropathy Recurrence After Kidney Transplantation in an Adult Patient With Primary Hyperoxaluria Type 1.
暂无分享,去创建一个
E. Thervet | D. Anglicheau | A. Karras | F. Martínez | P. Isnard | S. Chauvet | Y. Lombardi | N. Chavarot
[1] J. Lieske,et al. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial. , 2022, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[2] J. Lieske,et al. New therapeutics for primary hyperoxaluria type 1 , 2022, Current opinion in nephrology and hypertension.
[3] D. Hooper,et al. Primary hyperoxaluria diagnosed after kidney transplant: A review of the literature and case report of aggressive renal replacement therapy and lumasiran to prevent allograft loss , 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[4] J. Lieske,et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. , 2021, The New England journal of medicine.
[5] S. Keam,et al. Lumasiran: First Approval , 2021, Drugs.
[6] P. Cochat,et al. Transplantation for Primary Hyperoxaluria Type 1: Designing New Strategies in the Era of Promising Therapeutic Perspectives , 2020, Kidney international reports.
[7] B. Hoppe,et al. Is stiripentol truly effective for treating primary hyperoxaluria? , 2020, Clinical Kidney Journal.
[8] W. Lowther,et al. Endpoints for Clinical Trials in Primary Hyperoxaluria. , 2020, Clinical journal of the American Society of Nephrology : CJASN.
[9] M. Daudon,et al. Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning. , 2019, The Journal of clinical investigation.
[10] J. Lieske,et al. Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria. , 2015, Journal of the American Society of Nephrology : JASN.
[11] G. Rumsby,et al. Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. , 2013, Biochimica et biophysica acta.
[12] J. Groothoff,et al. Primary hyperoxaluria type 1: practical and ethical issues , 2013, Pediatric Nephrology.
[13] B. Hoppe. An update on primary hyperoxaluria , 2012, Nature Reviews Nephrology.
[14] E. Salido,et al. Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[15] F. Schaefer,et al. Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[16] E. Bergstralh,et al. Transplantation Outcomes in Primary Hyperoxaluria , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[17] R. Wanders,et al. Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[18] P. Cochat,et al. Primary hyperoxaluria. , 2013, The New England journal of medicine.
[19] P. Cochat,et al. Epidemiology of primary hyperoxaluria type 1 , 1995 .